[{"orgOrder":0,"company":"Integral Molecular","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 RVPs","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Integral Molecular \/ Inapplicable"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Optimeos Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Optimeos Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Integral Molecular \/ Optimeos Life Sciences"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Cartexell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CLDN18.2","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Integral Molecular \/ Cartexell","highestDevelopmentStatusID":"3","companyTruncated":"Integral Molecular \/ Cartexell"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Optimeos Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Integral Molecular \/ Optimeos Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Integral Molecular \/ Optimeos Life Sciences"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Integral Molecular \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Integral Molecular

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : CTIM-76, is a bispecific antibody incorporating highly selective CLDN6 binding arm and CD3 binding single-chain Fv domain in an IgG format with a silenced Fc that is designed to be functionally monovalent to avoid aberrant T-cell activation and to enhanc...

                          Product Name : CTIM-76

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 01, 2023

                          Lead Product(s) : CTIM-76

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : Under the terms of the agreement, Integral Molecular will provide an exclusive worldwide license to CARTEXELL to use the panel of high-affinity, high-specificity, and fully humanized CLND18.2 MAbs for the development of CAR-T cell therapies against solid...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 15, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Cartexell

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : The partnership combines Integral Molecular’s experience in antibody discovery and mRNA immunization with Optimeos’ technology for nanoparticle-based drug delivery systems having nanoparticle-based DNA Therapy.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 06, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : Optimeos Life Sciences

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : Integral Molecular has produced the most extensive catalog of SARS-CoV-2 pseudotyped reporter virus particles (RVPs), currently over 65 variants, which enables neutralizing antibodies or serum to be assessed in accordance with recent FDA .

                          Product Name : SARS-CoV-2 RVPs

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          August 18, 2021

                          Lead Product(s) : SARS-CoV-2 RVPs

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : The partnership will leverage Integral Molecular's industry-leading platform for antibody discovery and include novel targets in cancer and autoimmune diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 01, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Optimeos Life Sciences

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank